Diagnosis of Pseudoprogression Using MRI Perfusion in Patients with Glioblastoma Multiforme May Predict Improved Survival

Overview

Journal CNS Oncol

Specialty Oncology

Date 2014 Dec 3

PMID 25438810

Citations 28

Authors

Seymur Gahramanov

Csanad Varallyay

Rose Marie Tyson

Cynthia Lacy

Rongwei Fu

Joao Prola Netto

Morad Nasseri

Tricia White

Randy L Woltjer

Sakir Humayun Gultekin

Edward A Neuwelt

Affiliations

Soon will be listed here.

Abstract

Aims: This retrospective study determined the survival of glioblastoma patients with or without pseudoprogression.

Methods: A total of 68 patients were included. Overall survival was compared between patients showing pseudoprogression (in most cases diagnosed using perfusion MRI with ferumoxytol) and in patients without pseudoprogession. MGMT methylation status was also analyzed in the pseudoprogression cases.

Results: Median survival in 24 (35.3%) patients with pseudoprogression was 34.7 months (95% CI: 20.3-54.1), and 13.4 months (95% CI: 11.1-19.5) in 44 (64.7%) patients without pseudoprogression (p < 0.0001). The longest survival was a median of 54.1 months in patients with combination of pseudoprogression and (MGMT) promoter methylation.

Conclusion: Pseudoprogression is associated with better outcome, especially if concurring with MGMT promoter methylation. Patients never diagnosed with pseudoprogression had poor survival. This study emphasizes the importance of differentiating tumor progression and pseudoprogression using perfusion MRI.

Citing Articles

Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O-methylguanine-methyltransferase promoter methylation status.

Yadav V, Mohan S, Agarwal S, de Godoy L, Rajan A, Nasrallah M Neurooncol Adv. 2024; 6(1):vdae159.

PMID: 39502470 PMC: 11535496. DOI: 10.1093/noajnl/vdae159.

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.

Zeyen T, Paech D, Weller J, Schafer N, Tzaridis T, Duffy C J Neurooncol. 2023; 164(3):607-616.

PMID: 37728779 PMC: 10589172. DOI: 10.1007/s11060-023-04444-x.

Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions.

Malik D, Rath T, Urcuyo Acevedo J, Canoll P, Swanson K, Boxerman J Front Radiol. 2023; 2:809373.

PMID: 37492687 PMC: 10365126. DOI: 10.3389/fradi.2022.809373.

Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.

Young J, Al-Adli N, Scotford K, Cha S, Berger M J Neurosurg. 2023; 139(3):748-759.

PMID: 36790010 PMC: 10412732. DOI: 10.3171/2022.12.JNS222173.

Radiomic Analysis to Predict Histopathologically Confirmed Pseudoprogression in Glioblastoma Patients.

McKenney A, Weg E, Bale T, Wild A, Um H, Fox M Adv Radiat Oncol. 2023; 8(1):100916.

PMID: 36711062 PMC: 9873493. DOI: 10.1016/j.adro.2022.100916.

References

Stuplich M, Hadizadeh D, Kuchelmeister K, Scorzin J, Filss C, Langen K . Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. J Clin Oncol. 2012; 30(21):e180-3. DOI: 10.1200/JCO.2011.40.9565. View

Roldan Urgoiti G, Singh A, Easaw J . Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol. 2012; 108(1):173-7. DOI: 10.1007/s11060-012-0826-3. View

Varallyay C, Nesbit E, Fu R, Gahramanov S, Moloney B, Earl E . High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J Cereb Blood Flow Metab. 2013; 33(5):780-6. PMC: 3653563. DOI: 10.1038/jcbfm.2013.36. View

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):709-22. DOI: 10.1056/NEJMoa1308345. View

Fine H . Bevacizumab in glioblastoma--still much to learn. N Engl J Med. 2014; 370(8):764-5. DOI: 10.1056/NEJMe1313309. View

Nasseri M, Gahramanov S, Prola Netto J, Fu R, Muldoon L, Varallyay C . Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol. 2014; 16(8):1146-54. PMC: 4096172. DOI: 10.1093/neuonc/not328. View

Neuwelt A, Nguyen T, Fu R, Bubalo J, Tyson R, Lacy C . Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. CNS Oncol. 2014; 3(4):267-73. PMC: 6124367. DOI: 10.2217/cns.14.24. View

de Wit M, de Bruin H, Eijkenboom W, Sillevis Smitt P, van den Bent M . Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004; 63(3):535-7. DOI: 10.1212/01.wnl.0000133398.11870.9a. View

10.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

11.

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

12.

Chamberlain M, Glantz M, Chalmers L, Van Horn A, Sloan A . Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2006; 82(1):81-3. DOI: 10.1007/s11060-006-9241-y. View

13.

Brandes A, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G . MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26(13):2192-7. DOI: 10.1200/JCO.2007.14.8163. View

14.

Taal W, Brandsma D, de Bruin H, Bromberg J, Swaak-Kragten A, Sillevis Smitt P . Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008; 113(2):405-10. DOI: 10.1002/cncr.23562. View

15.

Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R . Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009; 101(1):124-31. PMC: 2713697. DOI: 10.1038/sj.bjc.6605127. View

16.

Gerstner E, McNamara M, Norden A, LaFrankie D, Wen P . Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009; 94(1):97-101. DOI: 10.1007/s11060-009-9809-4. View

17.

Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H . Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol. 2009; 72(4):423-8. DOI: 10.1016/j.surneu.2008.09.023. View

18.

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

19.

Gahramanov S, Raslan A, Muldoon L, Hamilton B, Rooney W, Varallyay C . Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys. 2010; 79(2):514-23. PMC: 3111452. DOI: 10.1016/j.ijrobp.2009.10.072. View

20.

Levin V, Bidaut L, Hou P, Kumar A, Wefel J, Bekele B . Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2010; 79(5):1487-95. PMC: 2908725. DOI: 10.1016/j.ijrobp.2009.12.061. View